At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of the pancreas that is newly diagnosed or previously treated metastatic disease, or unresectable disease
- ✓Age over 18 years
- ✓ECOG performance status 0-1
- ✓Life expectancy greater than 3 months
- ✕CNS or brain metastases
- ✕Evidence of bleeding diathesis or coagulopathy
- ✕Clinically significant grade II-IV peripheral vascular disease
- ✕Significant traumatic injury within the past 28 days
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating bevacizumab, capecitabine, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Giving gemcitabine and capecitabine together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine and capecitabine together with bevacizumab works in treating patients with metastatic or unresectable pancreatic cancer.
Study Details
Timeline
Interventions
30-90 minutes on day 1, every 21 days up to 12 months.
twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.